论文部分内容阅读
目的:评价阿奇霉素与头孢哌酮-舒巴坦钠联用对老年肺炎患者的临床疗效及安全性。方法:选取本次2013年1月—2014年10月期间收治的老年肺炎患者82例,将其按照治疗方式的不同分为治疗组41例和对照组41例;治疗组患者给予阿奇霉素与头孢哌酮-舒巴坦钠治疗,对照组患者给予单用头孢哌酮-舒巴坦钠治疗,对比两组患者治疗后的总有效率、血液炎性因子水平的变化情况以及不良反应的发生情况。结果:治疗组患者治疗后的总有效率为98.18%和不良反应的发生率为4.88%均优于对照组为72.73%和19.51%(P<0.05);同时,治疗组患者血液炎性因子的各项指标值均低于对照组(P<0.05)。结论:阿奇霉素与头孢哌酮-舒巴坦钠联用对老年肺炎患者的疗效优于单用头孢哌酮-舒巴坦钠治疗。
Objective: To evaluate the clinical efficacy and safety of azithromycin combined with cefoperazone-sulbactam in elderly patients with pneumonia. Methods: A total of 82 elderly patients with pneumonia admitted between January 2013 and October 2014 were selected and divided into treatment group (41 cases) and control group (41 cases). Patients in the treatment group were treated with azithromycin and cefoperazone Keto-sulbactam sodium and cefoperazone-sulbactam sodium alone in the control group. The total effective rate, the changes of blood inflammatory factors and the incidence of adverse reactions in the two groups were compared. Results: The total effective rate of the treatment group was 98.18% and the incidence of adverse reactions was 4.88%, which was significantly higher than that of the control group (72.73% vs 19.51%, P <0.05). At the same time, the blood inflammatory factors The index values were lower than the control group (P <0.05). Conclusion: The combination of azithromycin and cefoperazone-sulbactam sodium is superior to the single cefoperazone-sulbactam sodium in elderly patients with pneumonia.